Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

170 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial.
de Botton S, Montesinos P, Schuh AC, Papayannidis C, Vyas P, Wei AH, Ommen H, Semochkin S, Kim HJ, Larson RA, Koprivnikar J, Frankfurt O, Thol F, Chromik J, Byrne J, Pigneux A, Thomas X, Salamero O, Vidriales MB, Doronin V, Döhner H, Fathi AT, Laille E, Yu X, Hasan M, Martin-Regueira P, DiNardo CD. de Botton S, et al. Among authors: thol f. Blood. 2023 Jan 12;141(2):156-167. doi: 10.1182/blood.2021014901. Blood. 2023. PMID: 35714312 Free PMC article. Clinical Trial.
Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications.
Thol F, Bollin R, Gehlhaar M, Walter C, Dugas M, Suchanek KJ, Kirchner A, Huang L, Chaturvedi A, Wichmann M, Wiehlmann L, Shahswar R, Damm F, Göhring G, Schlegelberger B, Schlenk R, Döhner K, Döhner H, Krauter J, Ganser A, Heuser M. Thol F, et al. Blood. 2014 Feb 6;123(6):914-20. doi: 10.1182/blood-2013-07-518746. Epub 2013 Dec 13. Blood. 2014. PMID: 24335498 Free article.
Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.
Thol F, Gabdoulline R, Liebich A, Klement P, Schiller J, Kandziora C, Hambach L, Stadler M, Koenecke C, Flintrop M, Pankratz M, Wichmann M, Neziri B, Büttner K, Heida B, Klesse S, Chaturvedi A, Kloos A, Göhring G, Schlegelberger B, Gaidzik VI, Bullinger L, Fiedler W, Heim A, Hamwi I, Eder M, Krauter J, Schlenk RF, Paschka P, Döhner K, Döhner H, Ganser A, Heuser M. Thol F, et al. Blood. 2018 Oct 18;132(16):1703-1713. doi: 10.1182/blood-2018-02-829911. Epub 2018 Sep 6. Blood. 2018. PMID: 30190321 Free PMC article.
Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD.
Schlenk RF, Weber D, Fiedler W, Salih HR, Wulf G, Salwender H, Schroeder T, Kindler T, Lübbert M, Wolf D, Westermann J, Kraemer D, Götze KS, Horst HA, Krauter J, Girschikofsky M, Ringhoffer M, Südhoff T, Held G, Derigs HG, Schroers R, Greil R, Grießhammer M, Lange E, Burchardt A, Martens U, Hertenstein B, Marretta L, Heuser M, Thol F, Gaidzik VI, Herr W, Krzykalla J, Benner A, Döhner K, Ganser A, Paschka P, Döhner H; German-Austrian AML Study Group. Schlenk RF, et al. Among authors: thol f. Blood. 2019 Feb 21;133(8):840-851. doi: 10.1182/blood-2018-08-869453. Epub 2018 Dec 18. Blood. 2019. PMID: 30563875 Free article. Clinical Trial.
SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS.
Malcovati L, Stevenson K, Papaemmanuil E, Neuberg D, Bejar R, Boultwood J, Bowen DT, Campbell PJ, Ebert BL, Fenaux P, Haferlach T, Heuser M, Jansen JH, Komrokji RS, Maciejewski JP, Walter MJ, Fontenay M, Garcia-Manero G, Graubert TA, Karsan A, Meggendorfer M, Pellagatti A, Sallman DA, Savona MR, Sekeres MA, Steensma DP, Tauro S, Thol F, Vyas P, Van de Loosdrecht AA, Haase D, Tüchler H, Greenberg PL, Ogawa S, Hellstrom-Lindberg E, Cazzola M. Malcovati L, et al. Among authors: thol f. Blood. 2020 Jul 9;136(2):157-170. doi: 10.1182/blood.2020004850. Blood. 2020. PMID: 32347921 Free PMC article. Review.
[No title available]
[No authors listed] [No authors listed] PMID: 32812041
Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial.
Kapp-Schwoerer S, Weber D, Corbacioglu A, Gaidzik VI, Paschka P, Krönke J, Theis F, Rücker FG, Teleanu MV, Panina E, Jahn N, Herzig J, Kubanek L, Schrade A, Göhring G, Fiedler W, Kindler T, Schroeder T, Mayer KT, Lübbert M, Wattad M, Götze KS, Horst HA, Koller E, Wulf G, Schleicher J, Bentz M, Krauter J, Bullinger L, Krzykalla J, Benner A, Schlenk RF, Thol F, Heuser M, Ganser A, Döhner H, Döhner K. Kapp-Schwoerer S, et al. Among authors: thol f. Blood. 2020 Dec 24;136(26):3041-3050. doi: 10.1182/blood.2020005998. Blood. 2020. PMID: 33367545 Free article. Clinical Trial.
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.
Wei AH, Döhner H, Pocock C, Montesinos P, Afanasyev B, Dombret H, Ravandi F, Sayar H, Jang JH, Porkka K, Selleslag D, Sandhu I, Turgut M, Giai V, Ofran Y, Kizil Çakar M, Botelho de Sousa A, Rybka J, Frairia C, Borin L, Beltrami G, Čermák J, Ossenkoppele GJ, La Torre I, Skikne B, Kumar K, Dong Q, Beach CL, Roboz GJ; QUAZAR AML-001 Trial Investigators. Wei AH, et al. N Engl J Med. 2020 Dec 24;383(26):2526-2537. doi: 10.1056/NEJMoa2004444. N Engl J Med. 2020. PMID: 33369355 Clinical Trial.
Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin.
Schmalbrock LK, Dolnik A, Cocciardi S, Sträng E, Theis F, Jahn N, Panina E, Blätte TJ, Herzig J, Skambraks S, Rücker FG, Gaidzik VI, Paschka P, Fiedler W, Salih HR, Wulf G, Schroeder T, Lübbert M, Schlenk RF, Thol F, Heuser M, Larson RA, Ganser A, Stunnenberg HG, Minucci S, Stone RM, Bloomfield CD, Döhner H, Döhner K, Bullinger L. Schmalbrock LK, et al. Among authors: thol f. Blood. 2021 Jun 3;137(22):3093-3104. doi: 10.1182/blood.2020007626. Blood. 2021. PMID: 33598693 Free PMC article. Clinical Trial.
170 results